United States-based Pfizer has commenced a phase 2b/3 clinical trial of PF-06651600, an oral JAK3 inhibitor, intended to treat patients with moderate to severe alopecia areata, it was reported on Friday.
The product has achieved the primary efficacy endpoint in a Phase 2a study, which indicated that it improved hair regrowth on the scalp relative to baseline at week 24 as measured by the Severity of Alopecia Tool score. The investigational candidate also reached all secondary endpoints in the study, in addition to meeting the primary efficacy endpoint. PF-06651600 is also being evaluated for rheumatoid arthritis, Crohn's disease and ulcerative colitis.
The company will enrol up to 660 patients in the double-blind, placebo-controlled and dose-ranging phase 2b/3 clinical trial to evaluate the safety and effectiveness of PF-06651600 in adults and adolescents aged 12 years and older with 50% or greater scalp hair loss.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007